Scarica l'app Stockscreener
3.90
0.78%
0.03
Dopo l'orario di chiusura:
3.95
0.05
+1.28%
Precedente Chiudi:
$3.87
Aprire:
$3.86
Volume 24 ore:
745.61K
Relative Volume:
0.91
Capitalizzazione di mercato:
$322.76M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+1.04%
1M Prestazione:
+0.26%
6M Prestazione:
+119.10%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.78
$3.975
Intervallo di 1 settimana:
$3.33
$3.99
Portata 52W:
$1.42
$4.225
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Confronta ATYR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
3.90 | 322.76M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Iniziato | Wells Fargo | Overweight |
| 2024-09-05 | Iniziato | Jefferies | Buy |
| 2023-07-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-10 | Iniziato | Laidlaw | Buy |
| 2020-08-17 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Iniziato | ROTH Capital | Buy |
| 2020-03-02 | Iniziato | Oppenheimer | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2016-12-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Iniziato | Citigroup | Neutral |
| 2015-06-01 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
Stocks of Atyr Pharma Inc (ATYR) are poised to climb above their peers - SETE News
Recent Insider Activity Suggests Potential Gains for Atyr Pharma Inc (ATYR) - Knox Daily
How to interpret Atyr Pharma Inc (ATYR)’s stock chart patterns - US Post News
aTyr Pharma CFO Broadfoot sells $4,740 in stock - MSN
Atyr Pharma's general counsel Nancy Denyes sells $3,398 in stock - MSN
Trading Day Review: Atyr Pharma Inc (ATYR) Loses Momentum, Closing at 3.57 - The Dwinnex
JPMorgan Chase & Co. Boosts Holdings in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Increases By 25.0% - MarketBeat
Head to Head Contrast: CERo Therapeutics (NASDAQ:CERO) versus Atyr PHARMA (NASDAQ:ATYR) - Defense World
Here's Why We're Watching aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation - Yahoo Finance
aTyr Pharma to Present Three Posters for Efzofitimod at the - GlobeNewswire
Revolutionary Lung Disease Treatment Shows Promise: Major Updates Coming at ATS 2025 - StockTitan
Cantor Fitzgerald Estimates Atyr PHARMA FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts Atyr PHARMA FY2025 Earnings - MarketBeat
Institutional investors are aTyr Pharma, Inc.'s (NASDAQ:ATYR) biggest bettors and were rewarded after last week's US$29m market cap gain - Simply Wall St
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Expands By 25.0% - MarketBeat
Cantor Fitzgerald Weighs in on Atyr PHARMA FY2024 Earnings - Defense World
Several Insiders Invested In aTyr Pharma Flagging Positive News - Yahoo Finance
aTyr Pharma: Interesting Drug, Difficult Target Market (ATYR) - Seeking Alpha
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Analysts at Cantor Fitzgerald - Defense World
This Toast Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
aTyr Pharma stock soars to 52-week high of $4.16 By Investing.com - Investing.com Canada
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Cantor Fitzgerald - MarketBeat
Head-To-Head Analysis: Atyr PHARMA (NASDAQ:ATYR) versus CG Oncology (NASDAQ:CGON) - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Sees Significant Increase in Short Interest - MarketBeat
aTyr Pharma stock soars to 52-week high, hits $3.86 By Investing.com - Investing.com Canada
aTyr Pharma stock soars to 52-week high, hits $3.86 - Investing.com
SEC Form 424B5 filed by aTyr Pharma Inc. - Quantisnow
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57% - Yahoo Finance
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
aTyr Pharma to Present at JPMorgan Healthcare Conference: Spotlight on Revolutionary tRNA Platform - StockTitan
aTyr Pharma's SWOT analysis: efzofitimod's potential drives stock outlook - Investing.com
aTyr Pharma's SWOT analysis: efzofitimod's potential drives stock outlook By Investing.com - Investing.com Canada
aTyr Pharma expands board with new director appointment By Investing.com - Investing.com Canada
ATyr Pharma, Inc. Appoints Eric Benevich to Its Board of Directors - Marketscreener.com
aTyr Pharma expands board with new director appointment - Investing.com India
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors - The Manila Times
aTyr Pharma Strengthens Board with Neurocrine CCO Eric Benevich, Bolsters Commercial Leadership - StockTitan
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis - The Manila Times
aTyr Pharma Announces Third Positive DSMB Review for - GlobeNewswire
aTyr Pharma's Efzofitimod Phase 3 Trial Clears Critical Safety Review for Pulmonary Sarcoidosis Treatment - StockTitan
Atyr PHARMA (NASDAQ:ATYR) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Survey - Defense World
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis - The Manila Times
aTyr Pharma to Present Preclinical Research Demonstrating - GlobeNewswire
aTyr Pharma's Novel Fibrosis Treatment Shows Breakthrough Results in Preclinical Studies - StockTitan
Sarcoidosis Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharma, Novartis, Kinevant Sciences - Barchart
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Non sono disponibili dati finanziari per Atyr Pharma Inc (ATYR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Atyr Pharma Inc Azioni (ATYR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
| SCHIMMEL PAUL | Director |
Jul 24 '24 |
Buy |
1.93 |
52,300 |
101,038 |
413,023 |
| SCHIMMEL PAUL | Director |
Jul 22 '24 |
Buy |
1.74 |
41,052 |
71,500 |
354,075 |
| SCHIMMEL PAUL | Director |
Jul 23 '24 |
Buy |
1.82 |
6,648 |
12,075 |
360,723 |
| DENYES NANCY | General Counsel |
Jun 05 '24 |
Buy |
1.86 |
5,000 |
9,276 |
22,267 |
| COUGHLIN TIMOTHY | Director |
May 30 '24 |
Buy |
1.75 |
50,000 |
87,500 |
56,000 |
| Broadfoot Jill Marie | Chief Financial Officer |
May 31 '24 |
Buy |
1.79 |
5,000 |
8,950 |
27,960 |
| Shukla Sanjay | President and CEO |
May 31 '24 |
Buy |
1.81 |
20,000 |
36,140 |
136,548 |
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):